Horiba has announced it has acquired MedTest Holdings to expand its laboratory chemistry offerings.
The acquisition will combine the technology offerings of the Horiba Medical segment with MedTest Dx technology, Clinitox, and Pointe Scientific’s R&D and manufacturing capabilities, with particular expertise in FDA 510K and CLIA clearances, to address the multidisciplinary requirements of IVD (in-vitro diagnostics) testing customers.
Atsushi Horiba, chairman & group CEO of Horiba, said: “Our long-term vision and continuous investments coupled with our outstanding employees have resulted in pursuing innovative Chemistry and Immunochemistry technology solutions. I am extremely pleased that this long-term vision has resulted in acquiring MedTest.”
Dr. Jai Hakhu, Horiba medical segment leader, chairman and CEO of Horiba Instruments Incorporated and president of Horiba ABX SAS in France, added: “This acquisition provides Horiba Medical the opportunity to address the IVD market’s multidisciplinary requirements along with the complementary innovative technology of Pointe Scientific and MedTest’s high quality Chemistry solutions. Horiba Medical will continue offering innovative technology solutions through its Yumizen brand and current distribution channels.”
